Skip to content

Vedolizumab exposure across pregnancy

Compare intravenous vedolizumab exposure in the released pregnancy reference cases. A two-compartment model uses fixed baseline covariates and tracks cumulative exposure.

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How do the declared pregnancy and albumin effects change vedolizumab exposure?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

Q8w no pregnancy effects

Conditional maternal exposure with fixed baseline covariates and a declared periodic pre-pregnancy history.

0–280 day

Scenario details

Q8w no pregnancy effects

Conditional maternal exposure with fixed baseline covariates and a declared periodic pre-pregnancy history.

Readouts

Central concentration · mg/L
Conditional model quantity; exposure and elimination integrals are added nonfeedback accounting readouts.
Albumin g · g/L
Albumin g over the selected simulation window.
Linear elimination clearance · L/day
Conditional model quantity; exposure and elimination integrals are added nonfeedback accounting readouts.
Central volume · L
Conditional model quantity; exposure and elimination integrals are added nonfeedback accounting readouts.
Exposure (AUC) · mg*day/L
Conditional model quantity; exposure and elimination integrals are added nonfeedback accounting readouts.

Study purpose

  • How do the model's key biological readouts change under q8w no pregnancy effects?

Assumptions

  • Conditional maternal exposure model with explicit baseline covariates; no fetal/neonatal compartment, postpartum recovery or clinical-response prediction.
  • Time is physical days from GA0; gestational weeks equal days/7 and fertilization age equals GA−2. Albumin is held at its baseline until FA0.02 weeks (GA2.02/day14.14).
  • Albumin effects use fractional change from the predicted baseline C. Baseline C is 40.7 g/L, not a substituted observed albumin measurement.
  • The uncentered third-trimester factor applies at GA≥28; equality uses the declared right-hand convention.
  • All baseline controls are fixed within each context because changing them requires recalculating the pre-pregnancy periodic state.
  • The published schedule polynomial is a rounded exposure-maintenance illustration, not an individual threshold-triggered optimization or dosing recommendation.
  • No population draws, sequential fitting, residual likelihood, original patient histories or source concentration bands are reconstructed.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Simulation time
day
day
280 → 168

Time between reported samples.

day

1 change · Variation 1

Continue in the background and keep the result.

Biology

Explore conditional systemic antibody exposure and covariate effects.

Explore conditional systemic antibody exposure and covariate effects.

Model details

44 parameters · 4 states · 4 equations · 18 derived outputs

Classification & API access
Therapeutic
Vedolizumab
Modality
Monoclonal antibody
Target
Integrin α4β7
Disease / scope
Pregnant patients with inflammatory bowel disease
ParameterDefaultUnitDescription
Ada presentada_present0—Anti-drug antibody indicator.
Ada ratioada_ratio1.12—Table 2 ADACL; fixed.
Age on clearanceage_on_cl-0.0346—Table 2 AGECL; fixed.
Ageage_year30yearBaseline maternal age.
Albumin aalbumin_a0.0059g/L/week²Table 2 A; estimated.
Albumin balbumin_b-0.511g/L/weekTable 2 B; estimated.
Albumin calbumin_c40.7g/LTable 2 C; estimated.
Albumin change on clearancealbumin_change_on_cl-1.44—Table 2 DALBCL; estimated.
Albumin change on central distribution volumealbumin_change_on_vc-1.96—Table 2 DALBVC; estimated.
Albumin trend enabledalbumin_trend_enabled1—Declared scenario decomposition switch, not an estimated coefficient.
Amino presentamino_present0—Concomitant aminosalicylate.
Amino ratioamino_ratio1.02—Table 2 AMINOCL; fixed.
Aza presentaza_present0—Concomitant azathioprine.
Aza ratioaza_ratio0.998—Table 2 AZACL; fixed.
Baseline albumin on clearancebaseline_albumin_on_cl-1.18—Table 2 ALBCL; fixed.
Cd central distribution volume ratiocd_vc_ratio1.01—Table 2 CDVC; fixed.
Cdaicdai100—Declared approximate Crohn disease activity.
Cdai on clearancecdai_on_cl-0.0515—Table 2 CDAICL; fixed.
Clearance cdcl_cd0.155L/dayTable 2 CL_CD; fixed.
Clearance uccl_uc0.159L/dayTable 2 CL_UC; fixed.
Fcalfcal_mg_kg200mg/kgBaseline fecal calprotectin.
Fcal on clearancefcal_on_cl0.031—Table 2 FCALCL; fixed.
Is cdis_cd1—Diagnosis: Crohn1, UC0.
Kmkm_mg_l0.964mg/LTable 2 Km; fixed.
Mayomayo1—Declared approximate partial Mayo score.
Mayo on clearancemayo_on_cl0.0408—Table 2 MAYCL; fixed.
Mp presentmp_present0—Concomitant mercaptopurine.
Mp ratiomp_ratio1.04—Table 2 MPCL; fixed.
Mtx presentmtx_present0—Concomitant methotrexate.
Mtx ratiomtx_ratio0.983—Table 2 MTXCL; fixed.
Prior tnfprior_tnf1—Prior TNF therapy indicator.
Prior tnf ratioprior_tnf_ratio1.04—Table 2 TNFCL; fixed.
Q referenceq_reference_l_day0.12L/dayTable 2 Q; fixed.
Third trimester coefficientthird_trimester_coefficient0.151—Table 2 T3GACL; estimated.
Third trimester enabledthird_trimester_enabled1—Declared scenario decomposition switch, not an estimated coefficient.
Central distribution volume referencevc_reference_l4.33LTable 2 Vc; estimated.
Maximum elimination rate referencevmax_reference_mg_day0.265mg/dayTable 2 Vmax; fixed.
Peripheral distribution volume referencevp_reference_l1.65LTable 2 Vp; fixed.
Weightweight_kg70kgBaseline body weight.
Weight on clearanceweight_on_cl0.362—Table 2 WTCL; fixed.
Weight on qweight_on_q0.75—Table 2 WTQ; fixed.
Weight on central distribution volumeweight_on_vc0.467—Table 2 WTVC; fixed.
Weight on maximum elimination rateweight_on_vmax0.75—Table 2 WTVMAX; fixed.
Weight on peripheral distribution volumeweight_on_vp1—Table 2 WTVP; fixed.

Related models

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics